$100 million upfront + $100 million in equity + up to $350 million in milestone payments per target for at least 10 targets (Image: Dicerna Pharmaceuticals)
Dicerna Pharmaceuticals (DRNA) reported tangible clinical progress in Q1 yesterday, and the recent convert will fund r&d into 2019. (Image source: Genetic Literacy Project)
Two stocks that, like Logan, have fallen on hard times, but may have a redemption story buried beneath the rubble. This week at the Cowen HCC in Boston these Fallen angels look to tell the story again
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Dicerna Pharmaceuticals (DRNA) is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that
